Danielle Marie Brander, MD

Publications

Seymour, JF, Ma, S, Brander, DM, Choi, MY, Barrientos, J, Davids, MS, Anderson, MA, Beaven, AW, Rosen, ST, Tam, CS, Prine, B, Agarwal, SK, Munasinghe, W, Zhu, M, Lash, LL, Desai, M, Cerri, E, Verdugo, M, Kim, SY, Humerickhouse, RA, Gordon, GB, Kipps, TJ, and Roberts, AW. "Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study." The Lancet. Oncology 18, no. 2 (February 2017): 230-240.

PMID
28089635
Full Text

Brander, DM. "Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?." British Journal of Haematology 176, no. 3 (February 2017): 337-340.

Full Text

Strati, P, Lanasa, M, Call, TG, Leis, JF, Brander, DM, LaPlant, BR, Pettinger, AM, Ding, W, Parikh, SA, Hanson, CA, Chanan-Khan, AA, Bowen, DA, Conte, M, Kay, NE, and Shanafelt, TD. "Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial." The Lancet Haematology 3, no. 9 (September 2016): e407-e414.

Full Text

Friedman, DR, Lanasa, MC, Davis, PH, Allgood, SD, Matta, KM, Brander, DM, Chen, Y, Davis, ED, Volkheimer, AD, Moore, JO, Gockerman, JP, Sportelli, P, and Weinberg, JB. "Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies." Leuk Lymphoma 55, no. 5 (May 2014): 1067-1075.

PMID
23863122
Full Text

Brander, D, Rizzieri, D, Gockerman, J, Diehl, L, Shea, TC, Decastro, C, Moore, JO, and Beaven, A. "Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma." Leuk Lymphoma 54, no. 12 (December 2013): 2627-2630.

PMID
23488610
Full Text

Brander, DM, and Beaven, AW. "Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib." Patient preference and adherence 6 (January 2012): 239-251.

PMID
22536060
Full Text

Bean, GR, Bryson, AD, Pilie, PG, Goldenberg, V, Baker, JC, Ibarra, C, Brander, DMU, Paisie, C, Case, NR, Gauthier, M, Reynolds, PA, Dietze, E, Ostrander, J, Scott, V, Wilke, LG, Yee, L, Kimler, BF, Fabian, CJ, Zalles, CM, Broadwater, G, Tlsty, TD, and Seewaldt, VL. "Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF." Clinical cancer research : an official journal of the American Association for Cancer Research 13, no. 22 Pt 1 (November 2007): 6834-6841.

PMID
18006786
Full Text